Guardant Health, Inc. (FRA:5GH)

Market Cap	10.97B
Revenue (ttm)	769.26M
Net Income (ttm)	-339.89M
Shares Out	n/a
EPS (ttm)	-2.74
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11
Average Volume	12
Open	82.44
Previous Close	82.46
Day's Range	82.44 - 82.50
52-Week Range	28.95 - 96.16
Beta	n/a
RSI	44.13
Earnings Date	Feb 20, 2026

About Guardant Health

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-powered PD-L1 detection; GuardantINFINITY Test that p...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2011
• Employees: 2,021
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 5GH

Financial Performance

In 2024, Guardant Health's revenue was $739.02 million, an increase of 31.04% compared to the previous year's $563.95 million. Losses were -$436.37 million, -8.98% less than in 2023.

Financial numbers in USD